Xspray Pharma
Develops improved cancer drugs (PKIs) using a patented amorphous formulation technology.
XSPRAY | ST
Overview
Corporate Details
- ISIN(s):
- SE0009973563 (+3 more)
- LEI:
- 549300NGRQCNZ3X4L157
- Country:
- Sweden
- Address:
- Scheeles väg 2, 171 65 Solna
- Website:
- https://xspraypharma.com/
- Sector:
- Manufacturing
Description
Xspray Pharma is a pharmaceutical company that utilizes its patented technology platform to develop improved versions of marketed drugs, primarily focusing on Protein Kinase Inhibitors (PKIs) for cancer treatment. The company's core innovation lies in its ability to create stable, amorphous (non-crystalline) formulations of active pharmaceutical ingredients. This unique approach enables the development of product candidates that can bypass the secondary patents of original crystalline drugs, facilitating market entry upon the expiration of the primary substance patent. Xspray Pharma's products are designed to offer clinical benefits for patients compared to the original branded drugs and their subsequent generic equivalents.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-11-09 08:30 | English | 1.4 MB | |||
| 2022-10-31 15:41 | English | 34.3 KB | |||
| 2022-10-31 13:30 |
Number of shares and votes in Xspray Pharma
|
English | 41.1 KB | ||
| 2022-10-31 13:30 |
Antal aktier och röster i Xspray Pharma
|
Swedish | 41.0 KB | ||
| 2022-10-25 11:45 |
Xspray Pharmas valberedning inför årsstämman 2023
|
Swedish | 43.9 KB | ||
| 2022-10-25 11:45 |
Xspray Pharma’s Nomination Committee for the Annual General Meeting 2023
|
English | 44.7 KB | ||
| 2022-10-17 18:40 |
Xspray Pharma har genomfört en riktad emission som tillför bolaget 100 MSEK
|
Swedish | 52.4 KB | ||
| 2022-10-17 18:40 |
Xspray Pharma has carried out a directed share issue raising proceeds of MSEK 1…
|
English | 53.2 KB | ||
| 2022-08-05 08:30 | Swedish | 1.3 MB | |||
| 2022-08-05 08:30 | English | 1.3 MB | |||
| 2022-06-17 08:50 |
Dasynoc har beviljats särläkemedelsstatus i USA för behandlingen av kronisk mye…
|
Swedish | 44.1 KB | ||
| 2022-06-17 08:50 |
Dasynoc granted Orphan Drug Designation in the US for the treatment of chronic …
|
English | 45.1 KB | ||
| 2022-06-15 08:30 |
Thomas Walz blir Chief Medical Officer på Xspray Pharma
|
Swedish | 44.5 KB | ||
| 2022-06-15 08:30 |
Xspray Pharma appoints Thomas Walz as Chief Medical Officer
|
English | 44.5 KB | ||
| 2022-05-19 11:10 |
Kommuniké från Årsstämma 2022 i Xspray Pharma AB (publ)
|
Swedish | 44.6 KB |
Automate Your Workflow. Get a real-time feed of all Xspray Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xspray Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xspray Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-10 | Anders Ekblom | Other | Buy | 168,000 | 4,998,000.00 SEK |
| 2024-06-04 | Ribbskottet AB Anders Bladh | Other | Buy | 1,958 | 145,655.62 SEK |
| 2024-06-03 | Anders Bladh, Ribbskottet | Other | Buy | 3,042 | 225,077.58 SEK |
| 2024-05-29 | Per Andersson | Other | Buy | 51,749 | 489,545.54 SEK |
| 2024-05-27 | Per Andersson | Other | Sell | 9,950 | 687,545.00 SEK |
| 2024-05-16 | Anders Bladh | Other | Buy | 10,000 | 503,500.00 SEK |
| 2024-05-02 | Maris Hartmanis | Other | Other | 2,385 | 95,400.00 SEK |
| 2024-05-02 | Christine Lind | Other | Other | 666 | 26,640.00 SEK |
| 2024-05-02 | Anders Ekblom | Other | Other | 500 | 20,000.00 SEK |
| 2024-03-05 | Robert Molander | Other | Buy | 5,000 | 20,000.00 USD |
Peer Companies
